Search the database for deliberate release of GM medicinal products
| EU record number |
Title |
Company / Sponsor |
Treated organism |
Genetic modification |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
A Phase I/II, First-in-human, open-label, accelerated-titration, two-part clinical trial of TK-8001 in patients with HLA-A*02:01 genotype and advanced-stage/metastatic, MAGE-A1 + solid tumors that either have no further approved therapeutic alternative(s) |
T-Knife GmbH |
Humans |
chimere MAGE-A1 TCRs |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
Efficacy and safety of bilateral intravitreal injection of GS010: a randomized, double-masked, placebo-controlled trial in subjects affected with G11778A ND4 leber hereditary optic neuropathy for up to one year. |
GenSight Biologics |
Humans |
human wild-type MT-NDA (mitochondrial NADH Dehydrogenase 4) |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
An open-label, phase I, dose-escalation and safety study of two intramuscular injections at dose of 2.9 log or 4 log CCID50 of the recombinant HIV I clade B measles vaccine vector in healthy adults. |
Institut Pasteur - Paris |
Humans |
Gag, Pol, Nef genes of HIV |
